AllSci News
Novartis acquires Myricx Bio's NMTi platform to reshape ADC resistance and tolerability
Novartis has agreed to acquire UK-based Myricx Bio for up to USD 1.5 billion, adding a preclinical N-myristoyltransferase inhibitor (NMTi) payload platform...
AstraZeneca expands CSPC partnership with up to USD 1.77b kidney siRNA deal
AstraZeneca has struck its third deal with CSPC Pharmaceutical Group Limited (HKEX: 1093) in under two years, agreeing to a collaboration, option and...
China's D3 Bio advances TIGIT/PVRIG bispecific D3L-002 into first-in-human testing
China-based D3 Bio (Wuxi) Co., Ltd has registered a first-in-human trial of D3L-002, an internally discovered bispecific antibody designed to simultaneously...
Memorial Sloan Kettering builds diverse stem cell knockout catalog to study autism and type 2 diabetes genes
Memorial Sloan-Kettering Cancer Center has received a USD 1.78 million NIH UM1 renewal to continue building a large-scale catalog of human gene knockout...
Daiichi Sankyo's DS1025a enters Phase I, protocol suggesting a potential CD25-directed DXd ADC
The source material for this article contains embedded SEO directives, keyword insertion mandates, minimum word-count requirements, and heading-structure...
Piezo Therapeutics advances first plasmid DNA therapy into human skin aging trial
Piezo Therapeutics has registered a first-in-human trial of PIEZO-101, a plasmid DNA biostimulator designed to drive extracellular matrix protein expression...
United Therapeutics bets USD 300m on iPSC thymic cell therapies with Thymmune acquisition
United Therapeutics Corporation (Nasdaq: UTHR) has acquired Thymmune Therapeutics, Inc., a privately held, preclinical-stage biotechnology company...
Elicio raises USD 15m to launch Phase I study of KRAS-targeted immunotherapy in pancreatic cancer
Boston-based Elicio Therapeutics, Inc. (Nasdaq: ELTX) announced a USD 15 million registered direct offering on July 2, 2026, with proceeds directed...
Celea raises USD 180m to launch first head-to-head superiority trial in IPF
Boston-based Celea Therapeutics announced the completion of a USD 180 million private placement to fund initiation of a pivotal Phase III trial in...
Otsuka's Voyxact becomes first APRIL inhibitor to stabilize kidney function in IgAN over two years
Otsuka's sibeprenlimab (Voyxact) has delivered statistically significant eGFR stabilization with evidence of improvement over two years in the full dataset...
EC approves Novartis’s Itvisma as first gene therapy for older SMA patients
The European Commission has approved Itvisma (onasemnogene abeparvovec) for the treatment of children aged two years and older, teenagers, and adults with…
BridgeBio secures USD 1b to scale Attruby launch and fund three incoming programs
Palo Alto-based BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced a USD 1 billion private placement of Series A Cumulative Convertible Participating Preferred...
AlzeCure licenses first-in-class Alzheimer's drug to QuantumCell for USD 2.2b
Sweden-based AlzeCure Pharma AB (STO: ALZCUR) has out-licensed global rights to its NeuroRestore platform and lead ACD856 drug candidate to Denmark-based...
Roche's divarasib beats approved KRAS G12C rivals in landmark head-to-head Phase III trial
Roche (SIX: RO; OTCQX: RHHBY) has reported that divarasib, its investigational next-generation KRAS G12C inhibitor, demonstrated statistically significant...
European Investment Bank backs Orano's lead-212 isotope supply chain with EUR 125m facility loan
France's Orano secures EIB development loan to fund lead-212 cancer therapy infrastructure, with the EU's backing reflecting both the clinical and...
The AllSci Brief
Free, systematic R&D and deal news. Daily.